Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 1 Interventional

Study of Birinapant in Combination With Conatumumab in Subjects With Relapsed Ovarian Cancer

ClinicalTrials.gov ID: NCT01940172

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT01940172. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 9:52 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 1b, Open-label, Non-randomized Multicenter Study of Birinapant in Combination With Conatumumab in Subjects With Relapsed Epithelial Ovarian Cancer, Primary Peritoneal Cancer or Fallopian Tube Cancer

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This is a dose escalation study in female subjects with relapsed ovarian cancer (including epithelial ovarian cancer, primary peritoneal cancer, or fallopian tube cancer). Approximately 30 to 40 subjects will be administered a combination of conatumumab and birinapant. In the initial dose-escalation stage of the study, adult female subjects will receive conatumumab in combination with increasing doses of birinapant in dose-escalation cohorts to determine the MTD of birinapant when administered with a fixed dose of conatumumab. In safety expansion stage, adult female subjects will receive conatumumab in combination with birinapant at the MTD of the combination.

Study identification

NCT ID
NCT01940172
Recruitment status
Completed
Study type
Interventional
Phase
Phase 1
Lead sponsor
TetraLogic Pharmaceuticals
Industry
Enrollment
27 participants

Conditions and interventions

Eligibility (public fields only)

Age range
18 Years and older
Sex
Female
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Nov 2013 (Type not available)
Primary completion
Sep 2015 (Actual)
Completion
Dec 2015 (Actual)
Last update posted
Jan 14, 2016

2013 – 2015

United States locations

U.S. sites
9
U.S. states
7
U.S. cities
8
Facility City State ZIP Site status
TetraLogic research site Fresno California 39720 —
TetraLogic Research Site San Luis Obispo California 93401 —
TetraLogic Research Site Fairway Kansas 66205 —
TetraLogic Research Site Boston Massachusetts 02114 —
TetraLogic Research Site Durham North Carolina 27710 —
TetraLogic Research Site Philadelphia Pennsylvania 19107 —
TetraLogic Research Site Philadelphia Pennsylvania 19111 —
TetraLogic Research Site Nashville Tennessee 37203 —
TetraLogic Research Facility Dallas Texas 75201 —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT01940172, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jan 14, 2016 · Synced Nov 15, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.